Abbott DES program
This article was originally published in The Gray Sheet
Executive Summary
Enrollment in firm's 400-patient, randomized, non-inferiority clinical trial comparing its ZoMaxx drug-eluting stent, which uses Abbott's ABT-578 rapamyacin analogue, to Boston Scientific's Taxus paclitaxel-eluting stent by means of an angiographic endpoint will commence in Q3, VP-Investor Relations John Thomas states during an earnings call July 9. Abbott's Medical Products Group revenue rose 12.8% to $1.05 bil. in the second quarter fueled by strong vascular device and diabetes care sales...